Front Immunol: The use of gliptin reduces SDF-1/CXCL12 levels in patients with bullous pemphigoid and type 2 diabetes, but does not increase autoantibodies against BP180 in diabetics

Background: Bullous pemphigoid (BP) is the most common autoimmune subepidermal vesicular skin disease that primarily affects the elderly

Epidemiological data convincingly demonstrate that the most obvious risk factors for BP are certain neurological disorders and the use of

One of the most characteristic substrates of DPP4 is stromal cell-derived factor-1 (SDF‐1 or CXCL12), a type of lymphocyte and monocyte

We and others have previously found that patients at increased risk of high blood pressure, i.

Objective: In this study, we investigated how the use of gliptin affects the serum prevalence of anti-BP180 IgG autoantibodies in patients with T2D

Methods: These patients were treated with gliptin medication (n = 136) and those who were not treated with medication (n = 136).

Results: We found that IgG autoantibodies against BP180 immunodominant NC16A domains appeared

Figure 1 IgG autoantibodies

In Table 2 In the western blot, full-length BP180 is weakly recognized by the serum of most T2D patients, and the recognition frequency is lower

Figure 2 Detection

Figure 3 Concentrations

Figure 4 Immunostaining

Conclusion: Our results show that autoantibodies to BP180 are common in patients with T2D, but the seroprevalence rate is not affected by the use of sitagliptin

Nätynki A, Leisti P, Tuusa J, et al.